Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsParkland Tobramycin Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentParkland Community Health PlanPolicy N/A

    Medical Necessity Determination and Appeal Overturn Policy for Off-Label Inhaled Tobramycin Use in Pediatric Members <6 Years of Age with Cystic Fibrosis

    Customize your policy alerts

    Sign up for all parklandcommunityhealthplan policy alerts

    Know when parklandcommunityhealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity determinations and appeal overturns for off-label nebulized tobramycin in members younger than 6 years with cystic fibrosis and documented or suspected Pseudomonas aeruginosa respiratory infection enrolled in STAR and CHIP plans.

    Policy Summary
    PayerParkland Community Health Plan
    PolicyMedical Necessity Determination and Appeal Overturn Policy for Off-Label Inhaled Tobramycin Use in Pediatric Members <6 Years of Age with Cystic Fibrosis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 26, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization or appeal overturn documentation confirming cystic fibrosis, a qualifying clinical scenario, pulmonologist involvement, protocol adherence, and appropriate dosing and monitoring.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    <6 yearsMember age covered by this off-label policy
    28 daysInitial eradication course approval timeframe
    Up to 3Eradication cycles permitted within 6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsApproval period for up to three eradication cycles
    STAR and CHIPBenefit plans within scope

    Medical Necessity and Appeal Criteria

    Initial medical necessity and appeal overturn

    Off-label nebulized solution tobramycin is medically necessary and an appeal may be overturned when all of the following are met:

    Initial medical-necessity requirements

    • Diagnosis

      • The member has a confirmed diagnosis of cystic fibrosis.
      • ONE qualifying clinical scenario

        • First isolation of Pseudomonas aeruginosa.
        • Early recurrent infection that is non-chronic.
        • Clinical signs consistent with pulmonary exacerbation with a prior history of Pseudomonas aeruginosa.
        • High-risk infant with severe cystic fibrosis phenotype under cystic fibrosis specialist care.
    • Prescriber requirements

      • The drug is prescribed by or in consultation with a pulmonologist.
      • Adherence to an established eradication protocol is documented.
    • Dosing and monitoring plan

      • The treatment plan uses weight-based dosing.
      • Renal function is monitored using serum creatinine.
      • Audiology monitoring is planned when therapy is prolonged or courses are repeated.
      • The planned duration is consistent with eradication protocols, such as a 28-day inhaled course.

    Re-treatment and chronic suppressive therapy

    Continuation or re-treatment is available when the member meets either of the following pathways:

    Continuation pathways

    • Re-treatment for persistent or recurrent infection

      • Persistent or recurrent infection is documented with a repeat positive culture.
      • No more than three eradication cycles are approved within a six-month period.Up to 3 eradication cycles within 6 months
    • Chronic suppressive therapy

      • Chronic colonization develops before age 6.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Medical-Necessity Authorization

    Initial use of off-label nebulized solution tobramycin in members younger than 6 years requires prior authorization or an appeal overturn based on documented medical necessity. Approval requires confirmed cystic fibrosis, a qualifying Pseudomonas aeruginosa indication, and compliance with prescriber, protocol, dosing, and monitoring requirements.

    • Member is enrolled in STAR or CHIP and is younger than 6 years.
    • Prescribed for documented or suspected Pseudomonas aeruginosa respiratory infection, including first isolation, early re-isolation, or clinically suspected infection consistent with a CF pulmonary exacerbation.
    • Documentation supports the diagnosis, indication, specialist involvement, eradication protocol, dosing, and monitoring plan.
    Prior Authorization

    Re-Treatment Authorization

    Re-treatment for persistent or recurrent Pseudomonas aeruginosa infection requires repeat positive culture documentation and authorization within the applicable eradication-cycle limits.

    • Up to 3 eradication cycles are allowed within 6 months.

    Policy Background

    Nebulized solution tobramycin is traditionally FDA-labeled for patients 6 years of age and older. This policy addresses off-label use in children younger than 6 years with cystic fibrosis, where emerging evidence supports safety and efficacy, particularly for early eradication of Pseudomonas aeruginosa infection.

    Off-Label Use

    Unapproved indication / off-label use
    DefinitionA health care provider prescribes a medication for an unapproved use when deemed medically appropriate for the member.
    Unapproved conditionThe medication may be used for a disease or medical condition that it is not approved to treat.
    Different administrationThe medication may be given in a different way than the approved route or formulation.
    Different doseThe medication may be given at a different dose than the approved dose.

    Initial Eradication Therapy

    Initial eradication course

    Initial off-label eradication therapy is medically necessary when all diagnosis, prescriber, and dosing and monitoring requirements are met:

    Initial eradication course requirements

    • Diagnosis

      • The member has a confirmed diagnosis of cystic fibrosis.
      • ONE qualifying clinical scenario

        • First isolation of Pseudomonas aeruginosa.
        • Early recurrent infection that is non-chronic.

    Continuation and Re-treatment Pathways

    Continuation and re-treatment

    Continuation is available under either the re-treatment or chronic-suppression pathway:

    Continuation criteria

    • Re-treatment

      • Persistent or recurrent infection is documented with a repeat positive culture.
      • Up to three eradication cycles may be approved within six months.Up to 3 eradication cycles within 6 months
    • Chronic suppressive therapy

      • Chronic colonization develops before age 6.

    Eradication Cycle Limits

    Quantity limits
    MedicationNebulized solution tobramycin
    Eradication cycle limitUp to 3 eradication cycles
    TimeframeWithin 6 months
    Approval periodApproval for 6 months
    Quantity limits
    MedicationNebulized solution tobramycin
    Initial eradication course28 days
    Policy Summary
    PayerParkland Community Health Plan
    PolicyMedical Necessity Determination and Appeal Overturn Policy for Off-Label Inhaled Tobramycin Use in Pediatric Members <6 Years of Age with Cystic Fibrosis
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 26, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization or appeal overturn documentation confirming cystic fibrosis, a qualifying clinical scenario, pulmonologist involvement, protocol adherence, and appropriate dosing and monitoring.
    SourceLink
    On This Page
    Medical Necessity and Appeal CriteriaAuthorization and Documentation RequirementsPolicy BackgroundOff-Label UseInitial Eradication TherapyContinuation and Re-treatment PathwaysEradication Cycle Limits
    The case is reviewed individually.

    Case-by-case review

  1. Approval is reviewed at six-month intervals and requires documentation of clinical benefit, ongoing specialist oversight, and monitoring compliance.6-month approval intervals
  2. Approval may be issued for 6 months when repeat positive culture evidence supports re-treatment.
  3. Each course must follow an established eradication protocol and include the required clinical monitoring.
  4. Prior Authorization

    Chronic Suppression Authorization

    Chronic suppressive therapy when chronic colonization develops before age 6 is reviewed case by case. Continued approval is issued in 6-month intervals only when clinical benefit and ongoing oversight are documented.

    • Document clinical benefit from therapy.
    • Maintain ongoing specialist oversight.
    • Document compliance with required monitoring.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Failure to Meet Medical-Necessity Criteria

    An initial request or appeal overturn may be denied when the documentation does not establish medical necessity under the policy criteria. Unsupported requests do not qualify for approval.

    • No confirmed cystic fibrosis diagnosis or no qualifying Pseudomonas aeruginosa-related indication.
    • No pulmonologist prescription or consultation, or no evidence of eradication-protocol adherence.
    • Missing or inconsistent dosing, duration, renal-function, or required audiology monitoring plan.
    • Requested use falls outside the pediatric age scope or established eradication-cycle requirements.
    Denial Risk

    Insufficient Re-Treatment or Continuation Documentation

    Re-treatment or continuation may be denied when required supporting records are absent, incomplete, or insufficient to demonstrate ongoing medical necessity and clinical benefit.

    • No repeat positive culture documentation for persistent or recurrent infection.
    • No documentation of clinical benefit for chronic suppressive therapy.
    • No evidence of ongoing specialist oversight or monitoring compliance.
    • Records do not support the requested continuation period or exceed the permitted eradication-cycle limits.
    Clinical signs consistent with pulmonary exacerbation with a prior history of Pseudomonas aeruginosa.
  5. High-risk infant with severe cystic fibrosis phenotype under cystic fibrosis specialist care.
  6. Prescriber and protocol

    • The drug is prescribed by or in consultation with a pulmonologist.
    • Adherence to an established eradication protocol is documented.
  7. Dosing and monitoring

    • The treatment plan uses weight-based dosing.
    • Renal function is monitored using serum creatinine.
    • Audiology monitoring is planned if therapy is prolonged or courses are repeated.
    • The planned duration is consistent with eradication protocols, such as a 28-day inhaled course.28 days
  8. The case is reviewed case by case.

    Case-by-case review

  9. Approval is provided in six-month intervals and requires documentation of clinical benefit, ongoing specialist oversight, and monitoring compliance.6-month approval intervals
  10. Limit type
    Approval timeframe